SOURCE: Helix BioPharma Corp.

Helix BioPharma Corp.

May 27, 2015 08:00 ET

HELIX BIOPHARMA CORP. Announces a Presentation at the Joint Conference of the Canadian Society For Pharmaceutical Science and the Canadian Chapter of the Controlled Release Society

AURORA, ON--(Marketwired - May 27, 2015) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP)

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRES OR DISSEMINATION IN THE UNITED STATES

Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced that its Chief Scientific Officer, Dr. Heman Chao, has been invited to give an oral presentation at the 2015 Joint Conference of the Canadian Society For Pharmaceutical Science and the Canadian Chapter of the Controlled Release Society. 

The presentation title is "Development of a Camelid Antibody Enzyme Conjugate for the Treatment of Non-small Cell Lung Cancer." Dr. Chao will discuss the development of the company's lead clinical candidate L-DOS47 and highlight research findings recently published in the Journal of Bioconjugate Chemistry. The presentation will be given on May 27, 2015 at the Chelsea Hotel, Toronto, Canada. A copy of the presentation will be made available on Helix's website after the presentation.

About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate and its Topical Interferon Alpha-2b. Helix is currently listed on the TSX and FSE under the symbol "HBP".

This press release is not an offer of securities for sale in the United States. Helix's common shares have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent an exemption from registration thereunder.

Contact Information